https://orcid.org/0000-0002-6306-2394
References
- Zobair MY, Aaron BK, Dinan A, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
- Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:221–235.
- Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012;15(6):641–648.
- Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129.
- Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65–S75.
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328–357.
- Sumida Y, Seko Y, Yoneda M, Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017;47:266–280.
- Nakade Y, Murotani K, Inoue T, et al. Ezetimibe for the treatment of non-alcoholic fatty liver disease: a meta-analysis. Hepatol Res. 2017;47:1417–1428.
- Tesfay M, Goldkamp WJ, Neuschwander-Tetri BA. NASH: the emerging most common form of chronic liver disease. Mo Med. 2018;115:225–229.
- Sumida Y, Okanoue T, Nakajima A, Japan Study Group of NAFLD (JSG-NAFLD). Phase 3 drug pipelines in the treatment of NASH. Hepatol Res. 2019;49:1256–1262.
- Watanabe S, Hashimoto E, Ikejima K, Japanese Society of Gastroenterology, Japan Society of Hepatology. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50:364–377.
- Pockros PJ, Fuchs M, Freilich B, et al. CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 2019;39:2082–2093.
- Food and Drug Administration, Center for Drug Evaluation and Research. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005 [cited 2008 Mar 2]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm078932.pdf
- Yang J. Estimating dose in initial clinical trials for investigated new drugs. Chin J Clin Pharmacol Ther. 2008;8:841–846.
- Common terminology criteria for adverse events (CTCAE) version 4.0. 2010.
- Bobin P, Belacel-Ouari M, Bedioune I, et al. Cyclic nucleotide phosphodiesterases in heart and vessels: a therapeutic perspective. Arch Cardiovasc Dis. 2016;109:431–443.
- Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523–530.
- Yuan L, Dai X, Yang M, et al. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2016;11:1477–1483.
- Ohl DA, Carlsson M, Stecher VJ, et al. Efficacy and safety of sildenafil in men with sexual dysfunction and spinal cord injury. Sex Med Rev. 2017;5:521–528.
- Ding YH, Liu B, Lou JF, et al. Bioequivalence of sarpogrelate in healthy Chinese subjects under fasting and fed conditions: a 4-way replicate crossover investigation by a reference-scaled average bioequivalence approach. Clin Pharmacol Drug Dev. 2019;8:713–720.